- Home
- XERS vs GDEN Comparison
XERS vs GDEN Comparison
Compare XERS & GDEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | GDEN |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | 504 |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.3M | 763.2M |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | XERS | GDEN |
|---|---|---|
| Price | $5.48 | $26.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $10.83 | ★ $32.25 |
| AVG Volume (30 Days) | ★ 2.1M | 133.3K |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.67% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $49,590,000.00 | ★ $634,911,000.00 |
| Revenue This Year | $28.65 | $5.17 |
| Revenue Next Year | $18.33 | $2.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $3.81 | $19.57 |
| 52 Week High | $10.08 | $32.74 |
Technical Indicators
Market Signals| Indicator | XERS | GDEN |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 28.95 |
| Support Level | $4.30 | $24.09 |
| Resistance Level | $5.49 | $27.95 |
| Average True Range (ATR) | 0.24 | 0.54 |
| MACD | 0.00 | -0.23 |
| Stochastic Oscillator | 12.43 | 1.43 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.